Incyte vs BeOne Medicines
INCY and ONC side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INCY and ONC compare
BeOne Medicines is the larger company, worth 22 times as much as Incyte ($547B against $24.4B).
On earnings, Incyte is cheaper: it trades at 64.0× trailing earnings, against 861× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (34.3% versus 24.9% for Incyte).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 10.7% compared with 6.7% at Incyte.
Incyte scores higher on the StockData Score (13 against 12 for BeOne Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INCY | ONC |
|---|---|---|
| Size and price | ||
| Market cap | $24.4B | $547B |
| Share price | $120.39 | $370.33 |
| Change, 1 year | 33.5% | 17.6% |
| Change, 5 years | 77.4% | 1.5% |
| Beta (5Y) | 0.45 | 1.07 |
| Employees | 2,844 | 12K |
| StockData Score | ||
| Total score | 13 (better) | 12 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 3 | 4 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 64.0× (better) | 861× |
| P/S | 4.1× (better) | 89.3× |
| P/B | 4.3× (better) | 106× |
| EV/EBITDA | 29.1× (better) | 504× |
| P/FCF | – | 412× |
| PEG | 1.04 | – |
| FCF yield | – | 0.24% |
| Fair value | $66.29 | $15.35 |
| Margin of safety | −81.6% (better) | −2313% |
| Growth | ||
| Revenue growth (TTM) | 24.9% | 34.3% (better) |
| Revenue growth, 5Y average | 14.0% | 76.8% (better) |
| Net income growth (TTM) | −66.1% | – |
| EPS growth (TTM) | −68.2% | – |
| Profitability | ||
| Gross margin | 92.7% (better) | 88.9% |
| Operating margin | 10.4% | 15.1% (better) |
| Net margin | 6.7% | 10.7% (better) |
| FCF margin | – | 21.7% |
| Return on equity | 7.8% | 14.7% (better) |
| Return on invested capital | 13.9% | 43.7% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.22 (better) |
| Net debt / EBITDA | – | −3.67 |
| Interest coverage | 268× (better) | 8.7× |
| Current ratio | 3.84 (better) | 3.40 |
| Altman Z-score | 10.75 | 82.54 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 100.0% | 2.4% |
| Held by insiders | 33.4% | 13.9% |
| Insider net buying, 12 months | −$58.0M (better) | −$369M |
| Short interest, % of float | 7.4% | – |
Go deeper
- INCY stock overview
- INCY income statement
- INCY valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.